Clearview Wealth Advisors’s NovoCure NVCR Stock Holding History

Clearview Wealth Advisors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	628
2022 Q1	$0	Hold	1	–	–	﹤0.01%	669
2021 Q4	$1K	Hold	1	–	–	﹤0.01%	651
2021 Q3	$0	Hold	1	–	–	﹤0.01%	686
2021 Q2	$0	Sell	1 -74	-99%	-$14.4K	﹤0.01%	669
2021 Q1	$10K	Hold	75	–	–	0.01%	407
2020 Q4	$13K	Buy	+75	New	+$10.3K	0.01%	345

Other funds holding NVCR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Clearview Wealth Advisors's NVCR Position: Q2 2022 in Review

Clearview Wealth Advisors sold out of NovoCure (NVCR) in Q2 2022, closing a stake of 1 share.

Clearview Wealth Advisors first reported a position in NVCR in Q4 2020 and held it in 6 quarters. The position peaked at $13K in Q4 2020. 316 funds tracked by Wall St. Rank hold NVCR as of Q2 2022.

Clearview Wealth Advisors reported no remaining NovoCure position as of Q2 2022 after selling out during the quarter.
Clearview Wealth Advisors sold 1 NovoCure share in Q2 2022.
Clearview Wealth Advisors first reported a position in NovoCure in Q4 2020 and held it in 6 quarters.
Clearview Wealth Advisors's NovoCure position peaked at $13K in Q4 2020.
316 funds tracked by Wall St. Rank held NovoCure as of Q2 2022.

Based on Clearview Wealth Advisors's 13F filing for Q2 2022, filed 5 Aug 2022.